InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,193.20
(
0.13%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.08
(
-0.06%
)
Bitcoin
65,650.89
(
-1.48%
)
Post# of 252218
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

LongRun8

Send PM Follow Ignore
Followers 10
Posts 469
Boards Moderated 0
Alias Born 08/02/2012

LongRun8

Re: biotech_researcher post# 203238

Sunday, 08/07/2016 9:13:54 AM

Sunday, August 07, 2016 9:13:54 AM

Post# of 252218
NVAX - RSV vaccine is potentially a multi-billion dollar franchise. If data is good, NVAX should be worth significantly more than it is now. It hit $15 after Ph2 readout and was, IMO, fully valued at $4 billion for that time in the company's history. Ph3 success, followed by FDA approval and ACIP endorsement should probably bring this to around $6 bill. Not sure how the convertible debt will affect it, though. The ex-US partnership will affect share price as well.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up